{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:17:43Z","timestamp":1792451863103,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007504","name":"Boston Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pop.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T09:54:09Z","timestamp":1600854849000},"page":"645-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Diabetic Kidney Disease"],"prefix":"10.1016","volume":"47","author":[{"given":"Ryan","family":"Bonner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oltjon","family":"Albajrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hudspeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pop.2020.08.004_bib1","series-title":"2018\u00a0USRDS annual data report: CKD in the general population","first-page":"1","year":"2018"},{"issue":"5","key":"10.1016\/j.pop.2020.08.004_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pop.2020.08.004_bib3","first-page":"411","volume":"vol. 2","year":"2018"},{"key":"10.1016\/j.pop.2020.08.004_bib4","article-title":"Diabetic kidney disease: Pathophysiology and therapeutic targets","volume":"2015","author":"Toth-Manikowski","year":"2015","journal-title":"J\u00a0Diabetes Res"},{"issue":"9","key":"10.1016\/j.pop.2020.08.004_bib5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2011","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.pop.2020.08.004_bib6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","article-title":"Pathophysiology of the Diabetic Kidney","volume":"1","author":"Vallon","year":"2011","journal-title":"Compr Physiol"},{"issue":"1","key":"10.1016\/j.pop.2020.08.004_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.pop.2020.08.004_bib8","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"G\u00e6de","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.pop.2020.08.004_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1053\/j.ajkd.2007.08.005","article-title":"Sequence of Progression of Albuminuria and Decreased GFR in Persons With Type 1 Diabetes: A Cohort Study","volume":"50","author":"Costacou","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ki.1989.39","article-title":"Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians","volume":"35","author":"Kunzelman","year":"1989","journal-title":"Kidney Int"},{"issue":"22","key":"10.1016\/j.pop.2020.08.004_bib11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1056\/NEJM199611283352203","article-title":"Development and Progression of Renal Disease in Pima Indians with Non-Insulin-Dependent Diabetes Mellitus","volume":"335","author":"Nelson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pop.2020.08.004_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pop.2020.08.004_bib13","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.2337\/dc19-S011","article-title":"11. Microvascular complications and foot care: Standards of Medical Care in Diabetes - 2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pop.2020.08.004_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.2014.128","article-title":"Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes","volume":"87","author":"Molitch","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.pop.2020.08.004_bib15","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int"},{"issue":"1 SUPPL. 1","key":"10.1016\/j.pop.2020.08.004_bib16","article-title":"USRDS Annual Data Report: Incidence, prevalence, patient characteristics, and treatment modalities","volume":"59","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.pop.2020.08.004_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of Medical Care in Diabetes\u20142019 Abridged for Primary Care Providers","volume":"37","year":"2019","journal-title":"Clin Diabetes"},{"issue":"6","key":"10.1016\/j.pop.2020.08.004_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ckj\/sfv103","article-title":"Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA","volume":"8","author":"Gillespie","year":"2015","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1016\/j.pop.2020.08.004_bib19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.pop.2020.08.004_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.pop.2020.08.004_bib22","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.pop.2020.08.004_bib23","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9131","key":"10.1016\/j.pop.2020.08.004_bib24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.pop.2020.08.004_bib25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.pop.2020.08.004_bib26","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6343","key":"10.1016\/j.pop.2020.08.004_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.285.6343.685","article-title":"Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy","volume":"285","author":"Mogensen","year":"1982","journal-title":"Br Med J"},{"issue":"17","key":"10.1016\/j.pop.2020.08.004_bib29","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus","volume":"362","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2020.08.004_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes","volume":"20","author":"De Galan","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pop.2020.08.004_bib31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"22","key":"10.1016\/j.pop.2020.08.004_bib32","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2020.08.004_bib33","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Albert","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pop.2020.08.004_bib34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease","volume":"22","author":"Schmieder","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.pop.2020.08.004_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.pop.2020.08.004_bib36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pop.2020.08.004_bib37","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"De Zeeuw","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pop.2020.08.004_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.pop.2020.08.004_bib40","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing Microalbuminuria in Type 2 Diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"12 PART 1","key":"10.1016\/j.pop.2020.08.004_bib41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib42","first-page":"194","article-title":"Nephroprotective action of Renin-Angiotensin-Aldosterone system blockade in chronic kidney disease patients: The landscape after ALTITUDE and VA NEPHRON-D trails","volume":"25","author":"Rutkowski","year":"2015","journal-title":"J\u00a0Ren Nutr"},{"issue":"15","key":"10.1016\/j.pop.2020.08.004_bib43","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9638","key":"10.1016\/j.pop.2020.08.004_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pop.2020.08.004_bib45","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2020.08.004_bib46","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and Angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.pop.2020.08.004_bib47","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.pop.2020.08.004_bib48","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pop.2020.08.004_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","article-title":"Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study","volume":"25","author":"Rossing","year":"2002","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.pop.2020.08.004_bib50","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.pop.2020.08.004_bib51","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib52","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"issue":"Supplement 1","key":"10.1016\/j.pop.2020.08.004_bib53","first-page":"S90","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pop.2020.08.004_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.pop.2020.08.004_bib55","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/1060028013505428","article-title":"Unleash metformin: reconsideration of the contraindication in patients with renal impairment","volume":"47","author":"Lu","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"22","key":"10.1016\/j.pop.2020.08.004_bib57","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2020.08.004_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2020.08.004_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pop.2020.08.004_bib60","first-page":"149","article-title":"CANVAS Programme Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"130","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pop.2020.08.004_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors","volume":"74","author":"Bakris","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"10.1016\/j.pop.2020.08.004_bib62","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.pop.2020.08.004_bib63","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMe1904740","article-title":"Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease","volume":"380","author":"Ingelfinger","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pop.2020.08.004_bib64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10193","key":"10.1016\/j.pop.2020.08.004_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.pop.2020.08.004_bib66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pop.2020.08.004_bib67","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2020.08.004_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pop.2020.08.004_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454320300580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454320300580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:44:19Z","timestamp":1758815059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454320300580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0095454320300580"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2020.08.004","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Primary Care: Clinics in Office Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pop.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}